LMV 601
Alternative Names: SPK-0601; SPK-601Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator BioSphings
- Developer Lumavita
- Class Antivirals; Small molecules
- Mechanism of Action Phosphatidylcholine-specific phospholipase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Herpes simplex virus infections; Human papillomavirus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections in Switzerland (Topical)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Human-papillomavirus-infections(In volunteers) in Germany (Topical)
- 15 Mar 2011 Phase-I clinical trials in Human papillomavirus infections in Germany (Topical)